Impact of a Dynamic Microbiological Environment on the Clinical Efficacy of Ertapenem and Piperacillin/Tazobactam in the Treatment of Complicated Community-Acquired Intra-Abdominal Infection in Spain: A Cost-Consequence Analysis

Applied Health Economics and Health Policy
Santiago GrauGonzalo Nocea

Abstract

The microbial susceptibility of many antibiotics has been affected by prescribing patterns and their extensive use. The purpose of this evaluation was to assess how these changes could affect the initial efficacy of ertapenem and piperacillin/tazobactam in the treatment of complicated intra-abdominal infections (IAIs) acquired in the community and the potential consequences this may have in healthcare costs in Spain. The Initial efficacy of ertapenem and piperacillin/tazobactam for patients with APACHE (Acute Physiology and Chronic Health Evaluation) II scores <10 was extracted from a multicenter randomized study and were combined with the current microbial susceptibilities obtained from the SMART study, a multinational surveillance program. Country-specific pathogens distribution was extracted from a national study in patients with community-acquired IAI. The estimated effectiveness was used in a decision-analytic model to compare total costs between ertapenem and piperacillin/tazobactam in the treatment of complicated IAI. The model performs extensive one-way and probabilistic sensitivity analyses. The model suggested a savings of €209 (year 2012 values) per patient when complicated IAIs acquired in the community (APACHE II <...Continue Reading

References

Oct 6, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M H Kollef
Aug 24, 2004·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·K KrobotW Sendt
Oct 21, 2004·The Cochrane Database of Systematic Reviews·S SauerlandE A M Neugebauer
Jul 2, 2005·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M J DinubileJ P Quinn
Aug 31, 2006·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Carlos Magno C B FortalezaMarcelo de Carvalho Ramos
Jun 6, 2007·Expert Review of Anti-infective Therapy·Alfred GinGeorge G Zhanel
May 16, 2008·Enfermedades infecciosas y microbiología clínica·Oscar CuevasUNKNOWN Grupo Español para el Estudio de Estafilococo
Nov 26, 2009·Cirugía española·Xavier GuiraoCésar García Rey
Dec 26, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Joseph S SolomkinJohn G Bartlett
Jan 15, 2010·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Antonio José Sáez-CastilloJuan Díaz-Oller
Mar 1, 2009·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Jeroen P JansenYehuda Carmeli
Apr 3, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Paritosh PrasadCharles Natanson

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.